Aberrant expression of microRNA-4443 (miR-4443) in human diseases

Figures & data

Table 1. The aberrant expression of miR-4443 and its signaling axis in human diseases.

Type	Expression of miR-4443	Level	Signaling axis	References
BC	upregulation	tissue and cell	miR-4443/PEBP1	[6]
	upregulation	tissue and cell	miR-4443/TIMP2/MMP2	[20,33]
HCC	downregulation	tissue and cell	FEZF1-AS1/miR-4443/AKT1	[12,21]
NSCLC	/	tissue and cell	miR-4443/METTL3	[36]
	upregulation	cell	miR-4443/INPP4A	[7]
CRC	downregulation	cell	miR-4443/NCOA1 and TRAF4	[10]
GD	upregulation	tissue and cell	miR-4443/TRAF4	[17]
OS	downregulation	tissue and cell	miR-4443/NUPR1	[11]
HNSCC	downregulation	tissue and cell	LINC00460/miR-4443	[14]
AIS	upregulation	cell	miR-4443/TRAF4	[15]
AF	downregulation	tissue and cell	miR-4443/THBS1	[16]
PTC	downregulation	cell	miR-4443/TRIM14	[9]
GBM	downregulation	tissue and cell	MNX1-AS1/miR-4443	[13]
Glioma	upregulation	cell	miR-4443/PTPRJ	[8]

miR-4443 is abnormally expressed in different diseased tissues or cells, thereby playing an important role in inhibiting target genes or participating in ceRNA regulatory axis.

BC, Breast cancer; HCC, Hepatocellular carcinoma; NSCLC, Non-small cell lung cancer; CRC, Colorectal cancer; GD, Graves’ disease; OS, Osteosarcoma; GBM, Glioblastoma; AIS, Acute ischemic stroke; PTC, Papillary thyroid carcinoma; AF, Atrial fibrillation; HNSCC, Head and neck squamous cell carcinoma;

Table 2. Samples and cell lines with aberrant expression of miR-4443.

Type	Sample	Expression of miR-4443	References
BC	Parental MDA-MB-231 and Epi resistant BC subline MDA-MB-231/Epi	higher in MDA-MB-231/ Epi	[33]
	BC cell lines MCF‐7, MDA‐MB‐231; human breast cell line MCF‐10A and normal human liver cell line THLE‐3; 3 BC tissues and normal tissues	higher in MCF-7	[6,20]
CRC	CRC cell lines DLD-1, HT-29, and HCT-116	lower in HCT-116	[10]
OS	58 OS samples and the morphologically nontumor tissues	lower in OS	[11]
HNSCC	HNSCC cell lines CAL-27, WSU-HN4, WSUHN6; 15 HNSCC tissues and paired normal tissues	lower in HNSCC	[14]
GD	40 GD tissues and 30 normal tissues	higher in GD	[17]
GBM	44 GBM samples and adjacent normal tissues	lower in GBM	[13]
Glioma	Astrocytoma cells U251-MG, U251	higher in Glioma	[8]
NSCLC	NSCLC EPI-resistant cell line H1299	higher in H1299	[7]
HCC	58 tumor-adjacent tissues and 58 HCC tissues	lower in HCC	[12]
PTC	30 TN and 30 PTC tissues; PTC cell lines TT, TPC-1, FTC-133, SW1736, MZ-CRC-1 and human thyroid epithelial cell line HTori-3	lower in PTC	[9]
AF	123 persistent AF patients and 100 healthy controls	lower in AF	[16]
AIS	108 AIS patients and 74 healthy controls plasma samples	higher in AIS	[15]

miR-4443 was highly expressed in BC, GD, Glioma, NSCLC, and AIS, while miR-4443 was low expressed in OS, HNSCC, GBM, HCC, PTC, and AF.

BC, Breast cancer; HCC, Hepatocellular carcinoma; NSCLC, Non-small cell lung cancer; CRC, Colorectal cancer; GD, Graves’ disease; OS, Osteosarcoma; GBM, Glioblastoma; AIS, Acute ischemic stroke; PTC, Papillary thyroid carcinoma; AF, Atrial fibrillation; HNSCC, Head and neck squamous cell carcinoma; Epi: Epirubicin.

Figure 1. Pan-cancer analysis of miR-4443 using TCGA database.a: * means there is a significant difference (p < 0.05) b: *** means p < 0.001; ** means p < 0.01; * means p < 0.05; ns means no significant difference; BLCA, Bladder urothelial carcinoma; BRCA, Breast invasive carcinoma; CESC, Cervical and endocervical cancers; CHOL, Cholangiocarcinoma; COAD-READ, Colorectal adenocarcinoma; ESCA, Esophageal carcinoma; GBM-LGG, Glioma; HNSC, Head and neck squamous cell carcinoma; KICH, Kidney chromophobe; KIRC, Kidney renal clear cell carcinoma; KIRP, Kidney renal papillary cell carcinoma; LIHC, Liver hepatocellular carcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; PAAD, Pancreatic adenocarcinoma; PRAD, Prostate adenocarcinoma; STAD, Stomach adenocarcinoma; THCA, Thyroid carcinoma. UCEC, Uterine corpus endometrial carcinoma;

Figure 2. The downstream and upstream genes of miR-4443 in different diseases.miR-4443 inhibits the expression of target genes in various diseases and is involved in three ceRNA regulatory axes.

Figure 3. Molecular mechanisms by which miR-4443 affects cell behaviors.miR-4443 affects cell migration, invasion, and proliferation by inhibiting multiple target genes.

Figure 4. miR-4443 affects cellular drug resistance by inhibiting target genes. In tumor cells, miR-4443 affects the signaling pathway JAK2/STAT3 and normal molecular physiological activities by inhibiting the expression of target genes INPP4A and METLL3, thereby increasing drug resistance.

Figure 5. miR-4443 affects biological processes by regulating signaling pathways.miR-4443 regulates the four signaling pathways of JAK2/STAT3, TGF-β1, NF-κB, and Ras by inhibiting four target genes, thereby affecting the expression of inflammatory factors, fibrotic factors, and growth-promoting factors.

Wang J, Wang J, Gu Q, et al. MiR-4443 promotes migration and invasion of breast cancer cells by inhibiting PEBP1 expression. Nan Fang Yi Ke Da Xue Xue Bao. 2020;40(12):1712–1719.

 PubMedGoogle Scholar

Wang J, Zhang Q, Wang D, et al. Microenvironment-induced TIMP2 loss by cancer-secreted exosomal miR-4443 promotes liver metastasis of breast cancer. J Cell Physiol. 2020;235(7–8):5722–5735.

 PubMed Web of Science ®Google Scholar

Chen X, Zhong SL, Lu P, et al. miR-4443 participates in the malignancy of breast cancer. PloS one. 2016;11(8):e0160780.

 PubMed Web of Science ®Google Scholar

Gong J, Wang J, Liu T, et al. lncRNA FEZF1‑AS1 contributes to cell proliferation, migration and invasion by sponging miR‑4443 in hepatocellular carcinoma. Mol Med Rep. 2018;18(6):5614–5620.

 PubMed Web of Science ®Google Scholar

Zhao X, Tang D, Chen X, et al. Functional lncRNA-miRNA-mRNA networks in response to baicalein treatment in hepatocellular carcinoma. Biomed Res Int. 2021;2021:8844261.

 PubMed Web of Science ®Google Scholar

Song Z, Jia G, Ma P, et al. Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis. Life Sci. 2021;276:119399.

 PubMed Web of Science ®Google Scholar

Zhang W, Qiao B, Fan J. Overexpression of miR-4443 promotes the resistance of non-small cell lung cancer cells to epirubicin by targeting INPP4A and regulating the activation of JAK2/STAT3 pathway. Pharmazie. 2018;73(7):386–392.

 PubMed Web of Science ®Google Scholar

Meerson A, Yehuda H. Leptin and insulin up-regulate miR-4443 to suppress NCOA1 and TRAF4, and decrease the invasiveness of human colon cancer cells. BMC Cancer. 2016;16(1):882.

 PubMedGoogle Scholar

Qi Y, Zhou Y, Chen X, et al. MicroRNA-4443 causes CD4+ T cells dysfunction by targeting TNFR-associated factor 4 in graves’ disease. Front Immunol. 2017;8:1440.

 PubMed Web of Science ®Google Scholar

Zhou C, Xu J, Lin J, et al. Long noncoding RNA FEZF1-AS1 promotes osteosarcoma progression by regulating the miR-4443/NUPR1 axis. Oncol Res. 2018;26(9):1335–1343.

 PubMed Web of Science ®Google Scholar

Li M, Zhang X, Ding X; Li M, Zhang X, Ding X, Zheng Y, Du H, Li H, et al. Long noncoding RNA LINC00460 promotes cell progression by sponging miR-4443 in head and neck squamous cell carcinoma. Cell Transplant. 2020;29:963689720927405.

 PubMed Web of Science ®Google Scholar

Li S, Lu G, Wang D, et al. MicroRNA-4443 regulates monocyte activation by targeting tumor necrosis factor receptor associated factor 4 in stroke-induced immunosuppression. Eur J Neurol. 2020;27(8):1625–1637.

 PubMed Web of Science ®Google Scholar

Xiao J, Zhang Y, Tang Y, et al. hsa-miR-4443 inhibits myocardial fibroblast proliferation by targeting THBS1 to regulate TGF-β1/α-SMA/collagen signaling in atrial fibrillation. Braz J Med Biol Res = Rev Bras Pesqui Med Biol. 2021;54(4):e10692.

 PubMed Web of Science ®Google Scholar

Zuo XM, Sun HW, Fang H, et al. miR-4443 targets TRIM14 to suppress metastasis and energy metabolism of papillary thyroid carcinoma (PTC) in vitro. Cell Biol Int. 2021;45(9):1917–1925.

 PubMed Web of Science ®Google Scholar

Gao Y, Xu Y, Wang J, et al. lncRNA MNX1-AS1 promotes glioblastoma progression through inhibition of miR-4443. Oncol Res. 2019;27(3):341–347.

 PubMed Web of Science ®Google Scholar

Shefler I, Salamon P, Levi-Schaffer F, et al. MicroRNA-4443 regulates mast cell activation by T cell-derived microvesicles. J Allergy Clin Immunol. 2018;141(2132–41.e4):2132–2141.e4.

 PubMedGoogle Scholar

Data Availability statement

All data generated or analyzed during this study are included in the article.